Table 9.
Baseline characteristics of the testing sample (n = 203)
| Variable | n (%) |
| Age (y) (median (range)) | 64 (13–83) |
| Male sex | 160 (78.8%) |
| Viral infection | |
| HBsAg positive | 30 (14.8%) |
| Anti-HCVAb positive | 138 (68.0%) |
| Both positive | 2 (1.0%) |
| Both negative | 37 (18.2%) |
| Child-Pugh classification | |
| Class A | 155 (76.4%) |
| Class B | 48 (23.6%) |
| Class C | 0 (0%) |
| Tumour characteristics | |
| Size of tumour (cm) | |
| <2 | 28 (13.8%) |
| 2–5 | 118 (58.1%) |
| >5 | 57 (28.1%) |
| No of nodules | |
| Single | 146 (71.9%) |
| 2–3 | 46 (22.7%) |
| >3 | 11 (5.4%) |
| Portal invasion present* | 14 (6.9%) |
| AFP (ng/ml) | |
| <100 | 132 (65.0%) |
| 100–400 | 29 (14.3%) |
| >400 | 42 (20.7%) |
| Okuda stage | |
| I | 184 (90.6%) |
| II | 19 (9.4%) |
| III | 0 (0%) |
| CLIP score | |
| 0 | 86 (42.4%) |
| 1 | 67 (33.0%) |
| 2 | 43 (21.2%) |
| 3 | 4 (2.0%) |
| 4⩽ | 3 (1.5%) |
| BCLC staging | |
| A1 | 84 (41.4%) |
| A2 | 31 (15.3%) |
| A3 | 20 (9.9%) |
| A4 | 21 (10.3% |
| B | 33 (16.3%) |
| C | 14 (6.9%) |
| D | 0 (0%) |
| Tokyo score | |
| 0 | 11 (5.4%) |
| 1 | 59 (29.0%) |
| 2 | 73 (36.0%) |
| 3 | 45 (22.2%) |
| 4⩽ | 15 (7.4%) |
*Based on imaging diagnosis.
CLIP, Cancer of the Liver Italian Program; BCLC, Barcelona Clinic Liver Cancer; AFP, α fetoprotein; HBsAg, hepatitis B surface antigen; HCVAb, anti-hepatitis C virus antibody.